Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akcea Therapeutics Inc (AKCA)

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,846,054
  • Shares Outstanding, K 101,599
  • Annual Sales, $ 488,540 K
  • Annual Income, $ 40,770 K
  • 60-Month Beta 1.45
  • Price/Sales 3.77
  • Price/Cash Flow 35.60
  • Price/Book 3.85
Trade AKCA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings -0.49 on 08/04/20
  • Next Earnings Date 11/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.41
  • Prior Year -0.34
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.05 +0.66%
on 09/21/20
18.22 -0.27%
on 09/28/20
+0.03 (+0.17%)
since 09/09/20
3-Month
9.81 +85.22%
on 08/05/20
19.65 -7.53%
on 08/31/20
+4.88 (+36.72%)
since 07/09/20
52-Week
8.00 +127.13%
on 03/16/20
21.70 -16.29%
on 12/16/19
-1.57 (-7.95%)
since 10/09/19

Most Recent Stories

More News
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm – CGIX, BYFC, BMCH, AKCA

NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal...

CGIX : 4.61 (-2.33%)
BYFC : 2.60 (+3.59%)
BMCH : 53.68 (-3.24%)
AKCA : 18.17 (+0.17%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of...

GILD : 69.50 (-0.09%)
CBMG : 19.75 (unch)
AKCA : 18.17 (+0.17%)
VRTU : 51.33 (+0.03%)
IMMU : 87.86 (+0.05%)
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) --

AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
BMCH : 53.68 (-3.24%)
BLDR : 73.38 (+3.19%)
CGIX : 4.61 (-2.33%)
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – AIMT, AKCA, PTI

NEW YORK, NY / ACCESSWIRE / September 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations...

AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
PTI : 1.1100 (-3.48%)
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA

Halper Sadeh LLP, a global investor rights law firm, is investigating:

RST : 29.99 (unch)
CBMG : 19.75 (unch)
AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to...

AKCA : 18.17 (+0.17%)
IONS : 27.50 (+4.21%)
Yum China, Aimmune rise; Regis, Walmart fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially Monday:

AKCA : 18.17 (+0.17%)
YUMC : 50.86 (+4.54%)
RGS : 2.56 (-0.78%)
AIMT : 34.49 (-0.29%)
AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akcea Therapeutics,...

AKCA : 18.17 (+0.17%)
IONS : 27.50 (+4.21%)
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

Webcast scheduled for Tuesday, May 5 at 4:30 p.m. Eastern Time

AKCA : 18.17 (+0.17%)
IONS : 27.50 (+4.21%)
AKCEA INVESTOR ALERT: Shareholder Rights Investigation

BOSTON, MA / ACCESSWIRE / April 15, 2020 / Thornton Law Firm LLP, a law firm that represents shareholders and investors in public companies, announces it is investigating potential claims of breach of...

AKCA : 18.17 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 18.20
1st Resistance Point 18.18
Last Price 18.17
1st Support Level 18.14
2nd Support Level 18.12
3rd Support Level N/A

See More

52-Week High 21.70
Last Price 18.17
Fibonacci 61.8% 16.47
Fibonacci 50% 14.85
Fibonacci 38.2% 13.24
52-Week Low 8.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar